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Sulfonamide drugs which have brought about an antibiotic revolution in medicine are associated with a wide range
of biological activities. We have synthesized a series of α-tolylsulfonamide, 1–11 and their substituted N,N-diethyl-2-
(phenylmethylsulfonamido) alkanamide derivatives, 12–22 in improved and excellent yields in aqueous medium at room
temperature through highly economical synthetic routes. The chemical structures of the synthesized compounds 1–22 were
confirmed by analytical and spectral data such as IR, 1H- and 13C-NMR, andmass spectra. The in vitro antibacterial activity of these
compounds along with standard clinical reference, streptomycin, was investigated on two key targeted organisms. It was observed
that 1-(benzylsulfonyl)pyrrolidine-2-carboxylic acid, 2 emerged as the most active compound against Staphylococcus aureus at
MIC value of 1.8 μg/mL while 4-(3-(diethylamino)-3-oxo-2-(phenylmethylsulfonamido) propyl)phenyl phenylmethanesulfonate,
22 was the most active sulfonamide scaffold on Escherichia coli at MIC value of 12.5 μg/mL.
1. Introduction
The development of sulfonamides is a fascinating and infor-
mative area in medicinal chemistry [1–3]. Its functional
group has a long and rich history in organic chemistry
and drug discovery [4, 5]. The p-toluenesulfonamide and
benzenesulfonamides have been widely explored in synthetic
chemistry [4, 5]; however, few work has been done on the α-
tolylsulfonamide. For instance, synthesis of benzenesulfon-
amide derivative of pipecolic acid [6] and that of glycine
[7] had been reported. In addition, benzenesulfonamide of
alanine was achieved as a result of synthetic usage of such
amino acid as a linker to 6H-1,3,4-thiadiazine scaffold [8]
while naphthylsulfonamide was prepared as antagonist of
chemokine receptor [9]. Domagk’s discovery of antibacterial
activity for the azo dye prontosil led to the first effective
chemotherapeutic agent, sulfanilamide [10]. A retrospective
look at sulfonamides leaves no doubt that besides providing
the first effective treatment of bacterial infections [10, 11],
they also unleashed an antibiotic revolution in medicine
[12–15] to rationally design new therapeutic agents [16,
17]. These compounds provided an excellent lead for
structural modification and ushered in the modern era of
chemotherapy and drug design. Sulfonamides inhibit the
multiplication of bacteria by acting as competitive inhibitors
of p-aminobenzoic acid (PABA) in the folic acid metabolism
cycle [18, 19]. In fact, the discovery that sulfonamides act
through folate inhibition resulted in the development of
dihydrofolate reductase inhibitors such as trimethoprim [20,
21].
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Furthermore, sulfonamide moiety has a crucial function-
ality because of its wide variety of reported biological [22–25]
and pharmacological activities such as anticancer [26–28],
carbonic anhydrase inhibitory [29–31], antibacterial [32–
34], antimalarial [35, 36], antitumor [37, 38], antihyper-
tensive [39], anti-inflammatory [40–42], and antiprotozoal
activities [43]. Some sulfonamides have been established as
potent drugs in treatment of insomnia and other sleepless
challenges in man by antagonizing orexin neural activ-
ity [44–46]. Sulfonamidophenyl porphyrins have a great
potential utility as model for activatable photosensitizers
[47]. Sulfonamide has also been reported to possess good
herbicidal [48] and corrosion inhibitory properties [49, 50].
Multidrug resistance is one of the major immediate threats
to human health today [51]. For instance, methicillin is a
good antibacterial agent, yet, methicillin resistance among
Staphylococcus aureus [52] and Staphylococcus epidermidis
[53, 54] as well as other drug resistance in Escherichia coli
[55] had been identified to be of great concern in public
health. Epidemiological studies have also revealed that the
emergent of new diseases is on the increase and quite
alarming [56, 57].
In addition, the choice of S. aureus and E. coli as the
targeted organisms in this study was due to wide range of
infectious diseases and life threatening conditions associated
with such isolates. S. aureus, which produces heat stable
toxin, is among the invasive gram positive known as pyogenic
cocci implicated in several diseases of human [58, 59]. From
the literatures, S. aureus had shown to be very resistant
to a wide variety of antibiotics [60]. Infections caused by
methicillin-resistant S. aureus (MRSA) and vancomycin-
resistant S. aureus are associated with high morbidity and
mortality, high treatment cost, and long stays in hospitals
[60]. E. coli, a facultative anaerobe of wide distribution
in the environment, has been implicated in the cause of
urinary tract infections, meningitis, sepsis, wound infections,
nosocomial pneumonia, and arthritis. A subgroup enterohe-
morrhagic E. coli (EHEC) can cause severe potentially fatal
illness known as hemorrhagic colitis with symptoms of blood
diarrhea and severe abdominal pain [61].
Based on the numerous applications of sulfonamides
and challenges associated with drug usage and multidrug
resistance microorganisms aforementioned among others,
there is a continuous need for the synthesis of new organic
compounds as potential antimicrobial agents for the replace-
ment of the old existing ones currently available in the
market or to enhance the potency of the former ones.
Thus, it is conceivable to develop a series of functionalized
sulfonamides in order to investigate the in vitro antibacterial
activities of such scaffolds on the targeted organisms, namely,
S. aureus and E. coli.
2. Results and Discussion
2.1. Chemistry. In the continuation of our effort on the
discovery of rationally designed therapeutic agents [62,
63], we have herein reported the synthesis of a series of
new alkylarylsulfonamide with potent antibacterial activity.
We started with the reaction of equimolar proportion
of readily available amino acid, L-pipecolic acid with α-
toluene sulfonylchloride (α-TsCl) via a continuous magnetic
stirring at room temperature in the presence of aqueous
sodium carbonate for 48 h according to a known procedure
[64]. After the completion of the reaction which was TLC
monitored, the excess unreacted α-TsCl was recovered with
dichloromethane (DCM) using separatory funnel while the
aqueous layer was worked up by acidifying to a pH of
2.2 to get clear solution which upon freeze drying and
column purification afforded 1-(benzylsulfonyl)piperidine-
2-carboxylic acid 1 in excellent yield (98%). Being motivated
by this encouraging discovery, we then proceeded on the
coupling of nine other amino acids with α-TsCl under similar
condition to obtain α-tolylsulfonamides 2–10 in good to
excellent yields (Scheme 1).
In contrast to monosulfonylation that occurred in
formation of 1–10, the synthesis of 11 was achieved in
higher yield only when disulfonylation of the required
amino acid (tyrosine) was utilized. This was noticed when
monosulfonylation of tyrosine afforded 11 in lower yield
(45%) when compared with other sulfonamide products 1–
10 with their yields ranging from 87.5% to 98.8%. This
was because under the monosulfonylation of tyrosine, the
reaction terminated when the α-TsCl, being the limiting
reagent, has been exhausted living excess of the tyrosine in
the aqueous medium. This was as a result of two nucleophilic
attacking sites available on the L-tyrosine moiety. This means
that the phenolate anion was competing with the amino
group in terms of the nucleophilic potential on the α-
TsCl precursor, thereby resulting in an unusually lower yield
(45%). Based on this development, the stoichiometric ratio
was revisited in the production of 11 to give allowance
for selective disulfonylation of tyrosine. Hence, the reaction
for the production of 11 was reconducted in such a way
that the molar equivalent of α-TsCl was doubled that of
tyrosine in order to accommodate nucleophilicity from both
NH2 and PhO−of the latter, then the yield for 11 increased
drastically to 89.6% (Scheme 2). Structures of all eleven α-
tolylsulfonamides were confirmed by spectroscopic means
which include IR, mass spectra, 1H, and 13C NMR as well
as the elemental analytical data. Thus, the detail structural
elucidation was here-in confirmed using compound 1 as
the representative of the α-tolylsulfonamide templates. The
infrared spectrum of compound 1 gave rise to the absorption
bands of OH and carbonyl of carboxylic acid at 3422 and
1736 cm−1, respectively. Also, the CH stretching of both
aliphatic and aromatic occurred at the vibrational frequency
of 2974 and 2822 cm−1, respectively. The two IR bands for
SO2 unit were observed at 1159 and 1238 cm−1 as expected,
whereas the band accountable for C=C of aromatic was
observed at 1603 cm−1. The only easily accountable band
resulting from a bending vibrational mode at the finger print
region was Ar-H which appeared at 700 cm−1.
In the 1H-NMR of compound 1, all the five aromatic
protons resonated downfield as a singlet at δ 7.52 ppm
while the CH2 of benzylic group appeared as a two-proton
singlet at δ 4.28 ppm. Considering the upfield region, it was
discovered that CH proton adjacent to COOH resonated
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as a doublet of doublet at δ 4.08–4.02 ppm with coupling
constants of 3.44Hz and 15.12Hz. This was as a result of
the fact that its CH2 neighbouring protons were not totally
chemically equivalent even though they were attached to the
same carbon atom. All other remaining pipecolic protons
were well accounted for upfield between δ 3.57–3.53 and
1.81–1.68 ppm. The justification for their appearance near
TMS scale lies in the fact that they were attached to sp3
hybridized centre. Although, the molecular ion peak was
not observed, the base peak, however, occurred at m/z 178.1
which was as a result of the loss of benzylic radical. Other
prominent peaks which were formed as a result of some
fragmentation patterns appeared at m/z 180.1, 179.1, 165.1,
121.0, 77.0, and 64.0 with the intensities of 55%, 65%, 30%,
42%, 13%, and 31.7%, respectively.
The second stage of this experiment involved the chemi-
cal transformation of the carboxylic acid side chain moieties
of the sulfonamides 1–11 into N,N-diethyl alkanamides 12–
22 using highly efficient nonconventional method in its
slightly modified version [65]. The reaction optimization for
this aspect was carried out using amination of 1 with diethyl
amine under triethyl amine basified condition as a repre-
sentative. Thus, having established the C-amidoalkylation of
the sulfonamide 1 to achieve the alkanamide 12 in higher
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yield as a bountiful success, we were motivated to extend our
investigation to the reaction of other α-tolylsulfonamides 2–
11 with diethylamine under the same condition (Scheme 3).
These attempts also afforded the N,N-diethyl-substituted
products 13–22 in good to excellent yields as envisaged. The
spectroscopic assignment was consistent with that of pro-
posed structures for the obtained N,N-diethyl alkanamides
12–22. So, it is necessary to consider the spectral data of 12
as a typical representative of the N,N-diethyl alkanamides
in order to authenticate such compounds. The IR spectrum
of 12 had no absorption band above 3028 cm−1 indicating
the absence of –OH bond. This in turn confirmed the
effective amidation of COOH of compound 1. The bands at
3028 and 2951 cm−1 depicted CH of aromatic and aliphatic,
respectively. Also, the C=O and C=C frequency appeared at
1720 and 1593 cm−1, respectively, while the two bands of
SO2 were observed at 1188 and 1148 cm−1. Furthermore, the
chemical shifts and multiplicity patterns of 1H- and 13C-
NMR correlated well with that of the proposed alkylated
sulfonamides 12–22. The 1H-NMR spectrum of 12 in D2O
showed five aromatic protons as singlet at δ 7.54 and CH2
of benzylic group as singlet at δ 4.30. One triplet at δ 1.40–
1.37 (6H) was assigned to two methyl of diethyl group that
were chemically equivalent while one quartet at δ 3.21–3.16
(4H) was assigned to two methylene protons adjacent to the
methyl protons with a coupling constant of 7.20Hz. The 13C-
NMR of 12 in D2O in the presence of a drop of dioxane
revealed the presence of seventeen different carbon atoms
with C=O having the highest signal at δ 173.5 ppm while
the CH3 carbon atoms appeared to have the least signals at
δ 11.4 ppm.
2.2. Antibacterial Activity. The general antibacterial sensi-
tivity testing (inhibition zone, mm) of all the series of
twenty-two synthesized sulfonamides alongside with that of
streptomycin clinical standard was assayed on test organisms
(E. coli and S. aureus) using agar diffusion technique
[66]. The choice of E. coli as the gram −ve organism
is because it is easily transmissible through food, water,
soil, animal, and man [60]. E. coli is a normal flora of
human body which causes a lot of vancomycin-resistant
Enterococci and methicillin-resistant Staphylococcus aureus
(MRSA) [51]. Based on our previous report [62], the choice
of streptomycin as clinical standards is due to the fact that, at
low concentrations, streptomycin only inhibits the growth of
the bacteria through induction of prokaryotic ribosomes to
misread mRNA [67] and it also possesses broad spectrum of
antibacterial activity. There were reported cases of E. coli and
Staphylococcus aureus being susceptible to streptomycin [4,
68]. The biological relevance of the synthesized sulfonamides
here-in was authenticated by screening them in vitro against
Staphylococcus aureus ATCC 6538 (S. aureus) and Escherichia
coli ATCC 25922 (E. coli) with the reported selectivity index
(SI) duly calculated from zones of inhibition (ZOI). Hence, it
should be noted afterwards that the abbreviated forms were
given in the bracket for the sake of brevity and conciseness.
From the result of sensitivity testing, probable activities
of α-tolylsulfonamide family on the test organisms were
categorized based on the size of zone of inhibition (Table 1).
Interestingly, it was observed that some of the compounds
exhibited probable significant activities based on the large
zone of inhibition reported. For instance, compounds 6, 7,
12, 14, and 22 were highly active on E. coli while compounds
1, 2, 4, 5, 10, 11, 17, and 20 exhibited moderate activities
on the same organism. All other compounds showed low
activities on E. coli except 3 and 16 which showed no
activity at all on the E. coli even at 1000 μg/mL. The scenario
of comparative study of effect of the sulfonamides and
streptomycin on E. coli could be vividly understood by
observing the selectivity index (SI). All the sulfonamides have
selectivity indices ranging from 0.29 for compound 18 to
0.96 for compound 22 (i.e., less than 1). This implies that
streptomycin (SI = 1) was probably more active than any
of the sulfonamide scaffolds as regarding the inhibition of
E. coli growth. In the same vein, looking through the effect
on S. aureus, compounds 2, 5, 17, 21, and 22 were highly
active; 4, 6, 8, 10, 11, 12, 14, and 19 were moderately active;
1, 3, 7, 9, 13, 15, 18, and 20 exhibited low activity while 16
showed no activity on S. aureus (Table 1). The comparative
study of α-toluenesulfonamides to streptomycin on S. aureus
growth inhibition is worthy, of commendation. From the SI
values, compounds 9, 12, 18, and 20 competed favourably
with streptomycin while 2, 4, 5, 6, 8, 13, 14, 17, 19, 21,
and 22 (SI = 1.08–2.31) showed even a better activity than
streptomycin on S. aureus. All other compounds exhibited
lesser activity than streptomycin (SI = 0.46–0.92) on S. aureus
except 16 which showed no activity.
Due to high zones of inhibition obtained during general
sensitivity testing, the minimum inhibitory concentration
(MIC) was conducted, first at 100 μg/mL using Russell and
Furr method [69]. However, those compounds that could
not affect the inhibition of microbial growth at this concen-
tration were further repeated for MIC test at 1000 μg/mL.
The result of the MIC of this class of compounds on E.
coli and S. aureus was as shown in Table 2. Interestingly, all
the sulfonamides tested showed a concentration-dependent
inhibitory effect on the in vitro microbial growth assays [70].
Considering the MIC testing on the gram negative organism
(E. coli), it was observed that compounds 1, 6, 7, 11, 12, 14,
and 22 inhibited the microbial growth at varying values less
than or equal to 100 μg/mL, whereas, all other compounds
were active on E. coli at higher concentration (between 125
and 1000 μg/mL) except 3 and 16 which had no activity even
at 1000 μg/mL. Specifically, MIC values of the synthesized
compounds on E. coli were reported to be 50 μg/mL for 12
and 14; 100 μg/mL for 1 and 11; 125 μg/mL for 2, 4, 5, 10, 17,
and 20; 250 μg/mL for 8, 9, 13, 15, 19, and 21.
Although, the most active sulfonamides on E. coli were
6, 7, and 22 with MIC values of 25, 25, and 12.5 μg/mL,
respectively, none of them could compete with streptomycin
(MIC value of 6.25 μg/mL) in terms of activity. The two rings
presence in 22 and their π character might be responsible
for it being the most active as deduced from the finding of
Aissaoui and coworkers [71]. In addition, eight sulfonamides
(2, 5, 6, 8, 14, 17, 21, and 22) inhibited the S. aureus
growth at concentration ranging from 1.8 to 100 μg/mL. All
other compounds were able to affect the expected inhibition
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Scheme 3: Synthesis of N,N-diethylamide substituted α-tolylsulfonamides, 12–22.
from 125 μg/mL to 1000 μg/mL except 16 which had no
activity even at 1000 μg/mL. The significant antibacterial
activity of the synthesized compounds may be explained
by the ability of its sulfonamide binding site to mimic p-
aminobenzoic acid (PABA) which is an essential growth
factor in the targeted organisms as earlier documented in
the literatures [14–16]. The explanation for this encouraging
activity of the synthesized sulfonamides could be traceable
to the mode of action of sulfonamide drugs. This is based
on the inhibition of DNA synthesis [72] by interfering with
para-aminobenzoic acid (PABA) in biosynthesis of folic acid
[73].
Furthermore, from the structure activity relationship
(SAR) study, it was observed that the nature of side chains
(R1 and R2-CH-R3) of the α-tolylsulfonamides and the
presence ofN,N-diethylated amidomoieties {(CH3CH2)2N–
C=O} of the amide contributed immensely toward synergis-
tic or antagonistic effect on the reported in vitro antibacterial
activity. For instance, the antibacterial activity of structurally
related α-tolylsulfonamides containing R1 = (CH2)2SCH3, 6;
R2 = R3 = CH3, 7, on E. coli were very high with MIC value
of 25 ppm whereas the activity reduced to moderate when R1
= CH3, 4; R1 = CH2SH, 5 with MIC value of 125 ppm. The
synergistic effect due to the presence of N, N-diethylamido
moieties was noticed in some synthetic conversions such as 1
→ 12, 3 → 14 and 11 → 22. Thus, α-tolylsulfonamides 1 and
11 had moderate activity on E. coli while their corresponding
diethylamido 12 and 22 had better and higher activity on
E. coli. In fact, α-tolylsulfonamide 3 had no activity on E.
coli whereas its N, N-diethyl amidated counterpart, 14 had
very high activity with MIC value of 50 ppm. The synergistic
effect noticed herein might be as a result of electron donating
nature of the R1 side chain. On the contrary, antagonistic
effect was observed in the synthetic modification of 5 → 16
and 6 → 17 as far as presence of N, N-diethyl-substituted
amido moieties was concerned. This reverse order of activity
on E. coli might be as a result of the presence of sulfur atom
in 5 and 6 which might have altered the electron donating
prowess. Considering the structural relationship effect on the
activity of the synthesized compounds against S. aureus, it
was discovered that N,N-diethyl-substituted amides 14, 17,
21, and 22 had better activity than their α-tolylsulfonamide
precursors 3, 6, 10, and 11.
3. Conclusion
It was discovered that aqueous medium approach at ambient
temperature used here-in was a highly efficient procedure
for the preparation of various α-tolylsulfonamide derivatives
1–11 in good to excellent yield. The synthetic modification
of these derivatives as precursors to furnish disubstituted
amide bearing sulfonamides 12–22 was also successfully
achieved. The antibacterial evaluation study showed 1-(ben-
zylsulfonyl) pyrrolidine-2-carboxylic acid, 2 to be the most a
ctive sulfonamide on S. aureus while 4-(3-(diethylamino)-3-
oxo-2-(phenylmethylsulfonamido)propyl) phenylphenylme-
thane sulfonate, 22 emerged as the most active on the growth
inhibition of E. coli. Thus, this work will be very useful
for further studies in terms of toxicity effect and structural
activity relationship (SAR) study by using various types of
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Table 1: Result of general sensitivity testing with zones of inhibitory
in (mm) and selectivity index.
Compd. no.
In vitro antibacterial activity
Organisms
E. coli ATCC 25922 S. aureus ATCC 6538
ZOI (mm) SI ZOI (mm) SI
1 ++ 0.61 + 0.92
2 ++ 0.54 + + + 2.31
3 − — + 0.69
4 ++ 0.57 ++ 1.08
5 ++ 0.57 + + + 2.15
6 + + + 0.86 ++ 1.15
7 + + + 0.89 + 0.46
8 + 0.46 ++ 1.15
9 + 0.36 + 1.00
10 ++ 0.57 ++ 0.92
11 ++ 0.75 ++ 0.92
12 + + + 0.84 ++ 1.00
13 + 0.43 + 1.08
14 + + + 0.82 ++ 1.38
15 + 0.36 + 0.92
16 − — − —
17 ++ 0.57 + + + 2.23
18 + 0.29 + 1.00
19 + 0.43 ++ 1.08
20 ++ 0.54 + 1.00
21 + 0.39 + + + 2.00
22 + + + 0.96 + + + 2.00
Str. + + + 1.00 ++ 1.00
+: Less active 5–12mm; ++: moderately active 13–19mm; +++: highly
active 20–31mm; −: resistance; str.: streptomycin clinical reference; Z.O.I.:
zone of inhibition; S.I.: selective index obtained by comparing inhibition
zone of compound to that of streptomycin standard; E. coli: Escherichia
coli (ATCC 25922)G−; S. aureus: Staphylococcus aureus (ATCC 6538)G+; G−:
gram negative; G+: gram positive.
dialkylated substituents to monitor the trend of improve-
ment on their biological and pharmacological properties.
4. Experimental
4.1. General Conditions. The 1H-NMR spectra were recorded
in D2O on NMR Bruker DPX 400 spectrometer operating
at 400MHz. TMS was used as an internal standard with the
deuterium signal of the solvent as the lock and chemical
shifts δ recorded in ppm. The 13C-NMR spectra were run
in addition of a few drops of Dioxane but at 100MHz
frequency. The melting points were determined on XT-
4 Digital Binocular Microscope melting point apparatus
manufactured by Beijing Technical Instrument Co. Ltd. and
were uncorrected. IR spectra were run on Varian Excal-
ibur HE 3100 FT-IR Spectrometer while the mass spectra
were obtained using Waters GCT Premier Spectrometer.
The elemental analyses (C, H, and N) of the compounds
were performed using Flash EA 1112 Elemental Analyzer.
Lyophilization was carried out where necessary by using FD-
1 Freeze Drier while concentration and removal of solvents
were achieved with RE-2000B Rotary Evaporator.
In addition, the pHwasmonitored and confirmed during
acidification by using Portable pH Meter Model PHB4. All
drying was conducted at a reduced pressure with DHG-
9023A Vacuum Oven. The reaction progress was monitored
with TLC using CHCl3/CH3OH solvent system and the
developed plates were visualized under UV lamp and/or
in iodine tank where necessary. Column chromatographic
purifications were carried out on Merck silica gel F (Mesh
200–300). Organic solutions were dried over anhydrous
Na2SO4 and concentrated with a Buchi Rotary Evaporator
at reduced pressure. At all stages of the experiments, the
synthetic protocols were effected in bone dried solvents
under nitrogen atmosphere in dried glassware which were
wiped with stream flow of nitrogen gas prior to use and
SOCl2 was freshly distilled prior to use. Other reagents were
used directly after ascertaining the purity condition.
4.2. Synthesis
4.2.1. General Procedure of α-Tolylsulfonamide Derivatives 1–
11. To a solution of L-amino acid (5mmol) in H2O (6mL)
was added Na2CO3 (1.113 g, 10.5mmol) with a continuous
stirring until all the solutes had dissolved. The clear solution
was cooled to −10◦C and α-toluenesulfonyl chloride, α-
TsCl (1.144 g, 6mmol) was added in three batches over a
period of 1 h. It was warmed up to 0◦C and stirred there
for 1 h. Finally, the reacting mixture was then warmed up
to room temperature and allowed to stir there for 48 h. The
reaction was quenched by the addition of DCM (10mL)
and transferred into separatory funnel where the excess of
α-TsCl was removed by extraction. The aqueous layer was
then worked up to give a clear solution by the addition of
2N HCl until the pH 2.2 was attained. The clear liquid was
then lyophilized at−52◦C under reduced pressure for 12 h to
obtain the crude solid product which was purified by column
chromatography (CHCl3/CH3OH, 3 : 1) to afford α-toluene
sulfonamides 1–11 in excellent yields.
(1) 1-(Benzylsulfonyl)piperidine-2-carboxylic Acid, 1. Reage-
nts: L-pipecolic acid, yield 98%, mp 248◦C (dec), Rf = 0.87.
1H-NMR (D2O, 400MHz) δ: 7.52 (s, 5H, Ar-H), 4.28 (s,
2H, CH2-SO2), 4.08–4.02 (dd, J1 = 3.44Hz, J2 = 15.12Hz,
1H, HOOC-CH-CH2), 3.57–3.53 (m, 1H, CHa of CH2-N),
3.16–3.10 (m, 1H, CHb of CH2-N), 2.40–2.36 (m, 1H, CH),
2.01–1.92 (m, 2H, 2 × CH), 1.81–1.68 (m, 3H, CH & CH2)
ppm. 13C-NMR (Dioxane, 100MHz) δ: 172.5 (CO), 132.5,
131.2 (2CH aromatic), 129.5 (2CH aromatic), 128.9, 57.7,
57.6, 44.8, 26.5, 22.1 (2CH2) ppm. IR (KBr) cm−1: 3422 (OH
of acid), 2974 (CH aromatic), 2822 (CH aliphatic), 1736
(C=O of COOH), 1603 (C=C), 1238, 1159 (SO2 two bands),
700 (Ar-H). MS: in m/z [rel. %]: 269.1 [M+-CH2, 3.2%],
180.1 [55%], 179.1 [65%], 178.1 [M+-PhCH2, 100%], 165.1
[30%], 121.0 [42%], 77.0 [Ph+, 13%], 64.0 [SO+2 , 31.7%].
Anal. Calcd. for 283.35 C13H17NO4S: C, 55.11; H, 6.05; N,
4.94. Found: C, 55.29; H, 5.94; N, 4.86.
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Table 2: Result of MIC test of α-tolylsulfonamide on targeted organisms (μg/mL).
Compd. no.
Minimum inhibitory concentration (μg/mL)
Organisms
E. coli ATCC 25922 S. aureus ATCC 6538
at 100 μg/mL at 1000 μg/mL at 100 μg/mL at 1000 μg/mL
1 100 <1000 >100 250
2 >100 125 1.8 <1000
3 >100 — >100 250
4 >100 125 >100 125
5 >100 125 50 <1000
6 25 <1000 100 <1000
7 25 <1000 >100 500
8 >100 250 100 <1000
9 >100 250 >100 250
10 >100 125 >100 125
11 100 <1000 >100 125
12 50 <1000 >100 125
13 >100 250 >100 250
14 50 <1000 62.5 <1000
15 >100 250 >100 1000
16 >100 — >100 —
17 >100 125 25 <1000
18 >100 500 >100 1000
19 >100 250 >100 125
20 >100 125 >100 250
21 >100 250 25 <1000
22 12.5 <1000 25 <1000
Str. 6.25 <1000 >100 125
>100 means that if there was no growth inhibition at 100 μg/mL, it was repeated at 1000 μg/mL, <1000 μg/mL means that growth inhibition has already been
experienced at lower concentration less than or equal to 100 μg/mL; hence, there is no need to repeat the test at 1000 μg/mL.—means no activity was observed
even at 1000 μg/mL. Str. means streptomycin clinical reference.
(2) 1-(Benzylsulfonyl)pyrrolidine-2-carboxylic Acid, 2. L-amino
acid is L-proline; yield 1.24 g (92%); mp 108–110◦C; Rf
= 0.84. 1H-NMR (D2O, 400MHz) δ: 7.47 (s, 5H, Ar-H),
4.46–4.43 (dd, J1 = 7.2Hz, J2 = 15.76Hz, 1H, HOOC-CH-
CH2(a,b)), 4.24 (s, 2H, CH2-SO2), 3.48–3.45 (t, J = 7.28Hz,
2H, N-CH2-CH2), 2.46-2.45 (m, 1H, CHa of CH2), 2.22-2.21
(m, 1H, CHb of CH2), 2.15–2.09 (quintet, J = 6.8Hz, 2H,
CH2-CH2-CH2(a,b)) ppm. 13C-NMR (Dioxane, 100MHz)
δ: 173.1 (CO), 132.6, 131.2 (2CH aromatic), 129.5 (2CH
aromatic), 128.9, 60.6, 57.7, 47.1, 29.2, 24.3 ppm. IR (KBr)
cm−1: 3441 (OH of acid), 2980 (CH aromatic), 2828 (CH
aliphatic), 1728 (C=O of COOH), 1620 (C=C), 1219, 1151
(SO2 two bands), 700 (Ar-H). MS: in m/z [rel. %]: 270.1
[MH+, 6.5%], 269.1 [M+, 9%], 179.1 [18.4%], 178.1 [M+-
PhCH2, 100%], 176.1 [32.4%], 122.0 [49%], 105.0 [32%].
Anal. Calcd. for 269.32 C12H15NO4S: C, 53.52; H, 5.61; N,
5.20. Found: C, 53.77; H, 5.49; N, 5.34.
(3) 2-(Phenylmethylsulfonamido)acetic Acid, 3. Amino acid
is glycine; yield 1.08 g (94%); mp 150-151◦C; Rf = 0.51.
1H-NMR (D2O, 400MHz) δ: 7.45 (s, 5H, Ar-H), 4.19 (s,
2H, CH2-SO2), 3.76 (s, 2H, CH2-COOH) ppm. 13C-NMR
(Dioxane, 100MHz) δ: 170.6 (CO), 132.7, 131.2 (2CH
aromatic), 129.5 (2CH aromatic), 128.9, 57.7, 40.8 ppm. IR
(KBr) cm−1: 3433 (OH of acid), 3030 (N–H), 2990 (CH
aromatic), 2832 (CH aliphatic), 1736 (C=O of COOH), 1616
(C=C), 1215, 1171 (SO2 two bands), 702 (Ar-H). MS: in m/z
[rel. %]: 212.1 [M+-OH, 7.9%], 180.1 [73%], 179.1 [88%],
178.1 [M+ - PhCH2, 100%], 91.1 [PhCH+2 , 48%], 64 [26%]
45 [+COOH, 2.4%]. Anal. Calcd. for 229.26 C9H11NO4S: C,
47.15; H, 4.84; N, 6.11. Found: C, 46.90; H, 5.01; N, 5.97.
(4) 2-(Phenylmethylsulfonamido)propanoic Acid, 4. L-amino
acid is L-alanine; yield 1.18 g (97%); mp 126–128◦C; Rf
= 0.81. 1H-NMR (D2O, 400MHz) δ: 7.47 (s, 5H, Ar-H),
4.22 (s, 2H, CH2-SO2), 4.14–4.08 (q, J = 7.28Hz, 1H,
CH-CH3), 1.60-1.58 (d, J = 7.28Hz, 3H, CH3-CH) ppm.
13C-NMR (Dioxane, 100MHz) δ: 176.8 (CO), 131.0, 130.6
(2CH aromatic), 129.3 (2CH aromatic), 129.1, 60.4, 52.1,
19.6 ppm. IR (KBr) cm−1: 3424 (OH of acid), 2974 (CH
aromatic), 2822 (CH aliphatic), 1751 (C=O of COOH), 1599
(C=C), 1213, 1169 (SO2 two bands), 698 (Ar-H). MS: in m/z
[rel. %]: 212.1 [22%], 180.1 [81.5%], 179.1 [91%], 178.1
[85%], 165.1 [M-PhCH3, 55%], 122.0 [80%], 121.0 [100%],
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77.0 [Ph+, 71.4%], 64.0 [SO+2 , 54.6%], 51.0 [28%]. Anal.
Calcd. for 243.28 C10H13NO4S: C, 49.37; H, 5.39; N, 5.76.
Found: C, 49.29; H, 5.28; N, 5.94.
(5) 3-Mercapto-2-(phenylmethylsulfonamido)propanoic Acid,
5. L-amino acid is cysteine; yield 1.22 g (89%); mp 171–
173◦C; Rf = 0.49. 1H-NMR (D2O, 400MHz) δ: 7.49 (s,
5H, Ar-H), 4.50-4.47 (dd, J1 = 4.24Hz, J2 = 7.92Hz, 1H,
CH2-CH-COOH), 4.24 (s, 2H, CH2-SO2), 3.55–3.50 (dd,
J1 = 4.24Hz, J2 = 20Hz, 1H, CHa of CH2-CH), 3.39–3.33
(dd, J1 = 7.92Hz, J2 = 20Hz, 1H, CHb of CH2-CH) ppm.
13C-NMR (Dioxane, 100MHz) δ: 171.5 (CO), 132.6, 131.3
(2CH aromatic), 129.5 (2CH aromatic), 128.7, 57.8, 52.7,
37.2 ppm. IR (KBr) cm−1: 3439 (OH of acid), 2978 (CH
aromatic), 2832 (CH aliphatic), 1728 (C=O of COOH), 1618
(C=C), 1207, 1159 (SO2 two bands), 810 (Ar-H). MS: in m/z
[rel. %]: 214.1 [31.7%], 123.0 [100%], 122.0 [90%], 92.1
[PhCH+3 , 33%], 91.0 [PhCH
+
2 , 88%], 77.0 [Ph
+, 8%], 65.0
[HSO+2 , 34%], 45.0 [
+COOH, 28%], 36.0 [34%]. Anal. Calcd.
for 275.35 C10H13NO4S2: C, 43.62; H, 4.76; N, 5.09. Found:
C, 43.45; H, 4.94; N, 5.07.
(6) 4-(Methylthio)-2-(phenylmethylsulfonamido)butanoic
Acid, 6. L-amino acid is L-methionine; yield 1.33 g (87.7%);
mp 89-90◦C; Rf = 0.68. 1H-NMR (D2O, 400MHz) δ: 7.47 (s,
5H, Ar-H), 4.23 (s, 2H, CH2-SO2), 4.01–3.97 (t, J = 8.84Hz,
1H, CH-CH2), 2.76–2.72 (t, J = 7.40Hz, 2H, CH2-CH2-S),
2.33–2.29 (m, 1H, CH), 2.28–2.21 (m, 1H, CH), 2.19 (s, 3H,
CH3-S) ppm. 13C-NMR (Dioxane, 100MHz) δ: 172.9 (CO),
132.6, 131.2 (2CH aromatic), 129.5 (2CH aromatic), 128.7,
57.9, 52.8, 29.8, 29.4, 14.7 ppm. IR (KBr) cm−1: 3442 (OH
of acid), 2974 (CH aromatic), 2833 (CH aliphatic), 2774
(CH aliphatic), 1742 (C=O of COOH), 1590 (C=C), 1211,
1161 (SO2 two bands), 698 (Ar-H). Anal. Calcd. for 303.40
C12H17NO4S2: C, 47.51; H, 5.65; N, 4.62. Found: C, 47.49;
H, 5.64; N, 4.66.
(7) 3-Methyl-2-(phenylmethylsulfonamido)butanoic Acid, 7.
L-amino acid is L-valine; yield 1.34 g (98.7%); mp 137-
138◦C; Rf = 0.83. 1H-NMR (D2O, 400MHz) δ: 7.49 (s, 5H,
Ar-H), 4.25 (s, 2H, CH2-SO2), 4.04-4.03 (d, J = 4.4Hz, 1H,
CH-CH-COOH), 2.47–2.38 (m, 1H, CH-CH-(CH3)2), 1.15–
1.13 (d, J = 7.04Hz, 3H, CH3-CH), 1.13–1.11 (d, J = 7.08Hz,
3H, CH3-CH) ppm. 13C-NMR (Dioxane, 100MHz) δ: 172.4
(CO), 132.5, 131.2 (2CH aromatic), 129.5 (2CH aromatic),
128.9, 59.2, 57.7, 29.8, 18.1, 17.8 ppm. IR (KBr) cm−1: 3447
(OH of acid), 2974 (CH aromatic), 2833 (CH aliphatic),
2783 (CH aliphatic), 1730 (C=O of COOH), 1618 (C=C),
1225, 1165 (SO2 two bands), 700 (Ar-H). MS: in m/z [rel.
%]: 271.1 [M+, 14%], 91.0 [PhCH+2 , 30%], 75.0 [65%], 72.1
[100%], 55.0 [79%], 29.0 [50%]. Anal. Calcd. for 271.34
C12H17NO4S: C, 53.12; H, 6.32; N, 5.16. Found: C, 53.31; H,
6.50; N, 5.20.
(8) 3-Hydroxy-2-(phenylmethylsulfonamido)butanoic Acid, 8.
L-amino acid is L-threonine; yield 1.25 g (91.5%); mp 194-
195◦C; Rf = 0.48. 1H-NMR (D2O, 400MHz) δ: 7.49 (s, 5H,
Ar-H), 4.48–4.46 (m, 1H, CH), 4.24 (s, 2H, CH2-SO2), 4.05-
4.04 (d, J = 4.4Hz, 1H, CH-CH-COOH), 1.42–1.41 (d, J =
6.64Hz, 3H, CH3-CH) ppm. 13C-NMR (Dioxane, 100MHz)
δ: 171.5 (CO), 132.5, 131.2 (2CH aromatic), 129.5 (2CH
aromatic), 128.9, 66.1, 59.4, 57.7, 19.8 ppm. IR (KBr) cm−1:
3404 (OHof acid), 2976 (CH aromatic), 2824 (CH aliphatic),
1740 (C=O of COOH), 1601 (C=C), 1219, 1157 (SO2 two
bands), 700 (Ar-H). Anal. Calcd. for 273.31 C11H15NO5S: C,
48.34; H, 5.53; N, 5.12. Found: C, 48.29; H, 5.61; N, 4.98.
(9) 5-Amino-5-oxo-2-(phenylmethylsulfonamido)pentanoic
Acid, 9. L-amino acid is L-glutamine; yield 1.41 g (94.1%);
mp 211–214◦C; Rf = 0.38. 1H-NMR (D2O, 400MHz) δ: 7.48
(s, 5H, Ar-H), 4.47–4.43 (dd, J1 = 5.04Hz, J2 = 14.32Hz,
1H, HOOC-CH-CH2), 4.23 (s, 2H, CH2-SO2), 2.62–2.55
(m, 1H, CH), 2.49–2.44 (dd, J1 = 9.2Hz, J2 = 18.72Hz, 2H,
CH2-CH2-CON), 2.27–2.20 (m, 1H, CH) ppm. 13C-NMR
(Dioxane, 100MHz) δ: 181.1 (CO of acid), 163.2 (CO of
amide), 132.5, 131.2 (2CH aromatic), 129.5 (2CH aromatic),
128.9, 59.2, 57.7, 32.3, 26.2 ppm. IR (KBr) cm−1: 3246 (OH
of acid), 3075, 3053 (NH two bands), 2983 (CH aromatic),
2951 (CH aliphatic), 1703 (C=O of COOH), 1659 (C=O
amide), 1412 (OH bending in-plane), 1221, 1193 (SO2 two
bands), 696 (Ar-H), 631 (N-H bending with wagging). Anal.
Calcd. for 300.34 C12H16N2O5S: C, 47.99; H, 5.37; N, 9.33.
Found: C, 48.03; H, 5.56; N, 9.41.
(10) 3-Phenyl-2-(phenylmethylsulfonamido)propanoic Acid, 10.
L-amino acid is L-phenyl alanine; yield = 1.58 g (98.8%); mp
158-159◦C (dec); Rf = 0.84. 1H-NMR (D2O, 400MHz) δ:
7.46 (s, 10H, 2 × Ar-H), 4.34–4.31 (dd, J1 = 5.60Hz, J2 =
13.28Hz, 1H, PhCH2-CH-COOH), 4.22 (s, 2H, CH2-SO2),
3.41–3.36 (dd, J1 = 5.60Hz, J2 = 20.00Hz, CHa of CH2-Ph),
3.28–3.22 (dd, J1 = 7.60Hz, J2 = 20Hz, 1H, CHb of CH2-
Ph) ppm. 13C-NMR (Dioxane, 100MHz) δ: 172.3 (CO of
acid), 134.8, 132.6, 131.2 (2 × CH aromatic), 130.3 (2 ×
CH aromatic), 130.1 (2 × CH aromatic), 129.5 (2 × CH
aromatic), 128.9 (2 × CH aromatic), 57.7, 55.0, 36.4 ppm.
IR (KBr) cm−1: 3441 (OH of acid), 2974 (NH), 2822 (CH
aromatic), 2776 (CH aliphatic), 1740 (C=O of COOH), 1609
(C=C), 1221, 1171 (SO2 two bands), 702 (Ar-H), 623 (N-
H bending). MS: in m/z [rel. %]: 270.1 [4%], 212.1 [12%],
180.1 [90%], 179.1 [95%], 178.1 [100%], 165.1 [60%], 122.0
[34%], 121.0 [67%], 64 [SO2
+, 70%]. Anal. Calcd. for 319.38
C16H17NO4S: C, 60.17; H, 5.37; N, 4.39. Found: C, 59.98; H,
5.21; N, 4.42.
(11) 3-(4-(Benzylsulfonyloxy)phenyl)-2-(phenylmethylsulfon-
amido)propanoic Acid, 11. L-amino acid is tyrosine; yield =
2.19 g (89.6%); mp 195-196◦C; Rf = 0.82. 1H-NMR (D2O,
400MHz) δ: 7.43 (s, 10H, 2 × Ar-H), 7.22–7.20 (d, J =
8.4Hz, 2H, OTs-H), 6.93–6.91 (d, J = 8.4Hz, 2H, OTs-H),
4.31–4.28 (dd, J1 = 5.60Hz, J2 = 13.08Hz, 1H, PhCH2-CH-
COOH), 4.19 (s, 4H, 2 × CH2-SO2), 3.31-3.26 (dd, J1 =
5.60Hz, J2 = 20.00Hz, CHa of CH2-Ph), 3.19–3.14 (dd, J1 =
7.52Hz, J2 = 20Hz, 1H, CHb of CH2-Ph) ppm. 13C-NMR
(Dioxane, 100MHz) δ: 172.8 (CO of acid), 156.5, 140.9,
132.0, 131.8 (2CH aromatic), 131.3 (2 × CH aromatic),
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129.6 (2 × CH aromatic), 129.0 (2 × CH aromatic), 126.6,
123.6 (2 × CH aromatic), 117.1 (2 × CH aromatic), 111.8
(2 × CH aromatic), 58.4, 55.4, 36.1 ppm. IR (KBr) cm−1:
3435 (OH of acid), 3167 (NH), 3028 (CH aromatic), 2949
(CH aliphatic), 1724 (C=O of COOH), 1597 (C=C), 1194,
1148 (SO2 two bands), 789 (S-OR ester), 694 (Ar-H), 631
(N-H bending). MS: in m/z [rel. %]: 180.1 [74%], 179.1
[90%], 178.1 [100%], 165.1 [30%], 122.0 [10%], 91.1
[PhCH2
+, 47%], 64 [SO2
+, 24%]. Anal. Calcd. for 489.57
C23H23NO7S2: C, 56.43; H, 4.76; N, 2.86. Found: C, 56.38;
H, 4.79; N, 2.69.
4.2.2. General Procedure of N,N-Diethyl-2-(phenylmethy-
lsulfonamido)propanamide,12–22. To a solution of α-toly-
lsulfonamide derivatives 1–11 (2.96mmol) in H2O (10mL)
in a streaming flow of nitrogen gas was added oxalyl chloride
(0.34mL, 3.85mmol, 1.30 eq.) via dropping pipette followed
by carefully controlled addition of 1 drop of DMF. The
resulting mixture was stirred at room temperature for 2 h to
get crude acid chloride which was kept air-tighted prior to
use. In a separate 250mL three-necked round bottom flask,
equipped with a magnetic stirring bar, was added Na2CO3
(0.628 g, 5.92mmol, 2 equiv.) to H2O (10mL) followed
by diethyl amine DEA (0.4mL, 3.85mmol, 1.3 equiv.) in
a continuous stirring and cooled to −15◦C. Then, earlier
kept acid chloride was added in such a way to maintain
the internal temperature of the reaction mixture at around
−10◦C. The reacting mixture was then stirred at −10◦C
for 1 h; at 0◦C for 1 h; finally at room temperature for
1 h. The reaction was terminated, worked up by acidifying
with 2N HCl, and concentrated in a rotary evaporator. The
clear solution obtained was freeze-dried to get crude solid
product which was purified by column chromatography
(CHCl3/CH3OH, 3 : 1) to afford N,N-dimethylacetamide of
α-tolylsulfonamide derivatives 12–22.
(1) 1-(Benzylsulfonyl)-N,N-diethylpiperidine-2-carboxamide,
12. Yield 0.99 g (99.0%); mp 210-211◦C; Rf = 0.72. 1H-
NMR (D2O, 400MHz) δ: 7.54 (s, 5H, Ar-H), 4.30 (s, 2H,
CH2-SO2), 4.08–4.04 (dd, J1 = 3.52Hz, J2 = 20.00Hz, 1H,
CHa of CH2-N), 3.60–3.57 (m, 1H, CH-CON), 3.21–3.16
(q, J = 7.20Hz, 4H, 2 × CH2-CH3), 2.42–2.38 (dd, J1 =
3.32Hz, J2 = 20.00Hz, 1H, CHb of CH2-N), 2.03–1.99 (m,
2H, CH2), 1.86–1.73 (m, 3H, CH & CH2), 1.40–1.37 (t, J
= 7.20Hz, 6H, 2 × CH3-CH2) ppm. 13C-NMR (Dioxane,
100MHz) δ: 173.5 (C=O), 132.9, 131.1 (2 × CH aromatic),
129.8 (2 × CH aromatic), 128.6, 60.6, 57.8, 47.4, 43.4 (CH2),
29.4, 24.2, 18.1, 11.4 (CH3) ppm. IR (KBr) cm−1: 3028 (CH
aromatic), 2951 (CH aliphatic), 1720 (C=O), 1593 (C=C),
1188, 1148 (SO2 two bands), 696 (Ar-H). Anal. Calcd. for
C17H26N2O3S (338.47): C, 60.33; H, 7.74; N, 8.28. Found: C,
60.29; H, 6.94; N, 7.98.
(2) 1-(Benzylsulfonyl)-N,N-diethylpyrrolidine-2-carboxamide,
13. Yield 0.94 g (97.9%); mp 185–187◦C; Rf = 0.71. 1H-
NMR (D2O, 400MHz) δ: 7.53 (s, 5H, Ar-H), 4.54–4.50 (m,
1H, CH-CON), 4.28 (s, 2H, CH2-SO2), 3.56–3.54 (m, 2H,
CH2-N), 3.19–3.14 (q, J = 7.28Hz, 4H, 2 × CH2-CH3),
2.54–2.51 (m, 1H, CH), 2.28–2.24 (m, 1H, CH), 2.16–2.14
(m, 2H, CH2), 1.39–1.35 (t, J = 7.28Hz, 6H, 2 × CH3-CH2)
ppm. 13C-NMR (Dioxane, 100MHz) δ: 173.2 (C=O), 132.6,
131.1 (2 × CH aromatic), 129.4 (2 × CH aromatic), 128.8,
60.8, 57.7, 47.1, 43.3 (2 × CH2), 29.2, 24.2, 11.4 (2 × CH3)
ppm. Anal. Calcd. for C16H24N2O3S (324.45): C, 59.23; H,
7.46; N, 8.63. Found: C, 59.09; H, 7.46; N, 8.48.
(3)N,N-Diethyl-2-(phenylmethylsulfonamido)acetamide, 14.
Yield 0.78 g (92.6%); mp 213–215◦C; Rf = 0.51. 1H-NMR
(D2O, 400MHz) δ: 7.53 (s, 5H, Ar-H), 4.29 (s, 2H, CH2-
SO2), 4.01 (s, 2H, CH2-CON), 3.20-3.14 (q, J = 7.30Hz, 4H,
2× CH2-CH3), 1.39–1.36 (t, J = 7.30Hz, 6H, 2× CH3-CH2)
ppm. 13C-NMR (Dioxane, 100MHz) δ: 174.1 (C=O), 133.4,
131.6 (2 × CH aromatic), 129.5 (2 × CH aromatic), 128.6,
57.7, 49.8, 43.1 (CH2), 11.4 (CH3) ppm. IR (KBr) cm−1:
3217 (N-H), 3036 (CH aromatic), 2947 (CH aliphatic), 1712
(C=O), 1601 (C=C), 1219, 1194, (SO2 two bands), 694 (Ar-
H). Anal. Calcd. for C13H20N2O3S (284.38): C, 54.91; H,
7.09; N, 9.85. Found: C, 55.13; H, 6.94; N, 10.08.
(4)N,N-Diethyl-2-(phenylmethylsulfonamido)propanamide,
15. Yield 0.87 g (98.5%); mp 238–240◦C; Rf = 0.56. 1H-
NMR (D2O, 400MHz) δ: 7.50 (s, 5H, Ar-H), 4.26 (s,
2H, CH2-SO2), 4.22–4.16 (q, J = 7.28Hz, 1H, CH-CH3),
3.18–3.12 (q, J = 7.32Hz, 4H, 2 × CH2-CH3), 1.65–1.63 (d,
J = 7.28Hz, 3H, CH3-CH), 1.37–1.33 (t, J = 7.32Hz, 6H, 2
× CH3-CH2) ppm. 13C-NMR (Dioxane, 100MHz) δ: 173.8
(C=O), 132.7, 131.2 (2 × CH aromatic), 129.5 (2 × CH
aromatic), 128.9, 57.7, 49.8, 43.1 (CH2), 16.2, 11.4 (CH3)
ppm. IR (KBr) cm−1: 3058 (N-H), 3036 (CH aromatic), 2951
(CH aliphatic), 1719 (C=O), 1601 (C=C), 1219, 1196, 1148
(SO2 two bands), 696 (Ar-H). Anal. Calcd. for C14H22N2O3S
(298.41): C, 56.35; H, 7.43; N, 9.39. Found: C, 56.11; H, 7.33;
N, 9.28.
(5)N,N-Diethyl-3-mercapto-2-(phenylmethylsulfonamido)
propanamide, 16. Yield 0.87 g (89.0%); mp 198–200◦C; Rf
= 0.71. 1H-NMR (D2O, 400MHz) δ: 7.46 (s, 5H, Ar-H),
4.54–4.51 (dd, J1 = 4.24Hz, J2 = 7.92Hz, 1H, CH2-CH-
COOH), 4.21 (s, 2H, CH2-SO2), 3.57–3.52 (dd, J1 = 4.24Hz,
J2 = 20.00Hz, 1H, CHa of CH2-CH), 3.41–3.36 (dd, J1 =
7.92Hz, J2 = 20.00Hz, 1H, CHb of CH2-CH), 3.18–3.12 (q,
J = 7.35Hz, 4H, 2 × CH2-CH3), 1.37–1.33 (t, J = 7.35Hz,
6H, 2 × CH3-CH2) ppm. 13C-NMR (Dioxane, 100MHz)
δ: 173.5 (C=O), 132.7, 131.2 (2 × CH aromatic), 129.5 (2
× CH aromatic), 128.9, 57.4, 49.5, 43.1 (CH2), 35.5, 11.4
(CH3) ppm. IR (KBr) cm−1: 2997 (CH aromatic), 2911
(CH aliphatic), 1719 (C=O), 1591 (C=C), 1194, 1144 (SO2
two bands), 696 (Ar-H). Anal. Calcd. for C14H22N2O3S2
(330.47): C, 50.88; H, 6.71; N, 8.48. Found: C, 50.71; H, 6.99;
N, 7.97.
(6)N,N-Diethyl-4-(methylthio)-2-(phenylmethylsulfonamido)
butanamide, 17. Yield 0.96 g (90.6%); mp 170–172◦C; Rf =
0.65. 1H-NMR (D2O, 400MHz) δ: 7.49 (s, 5H, Ar-H), 4.24
(s, 2H, CH2-SO2), 4.23–4.20 (t, J = 6.72Hz, 1H, CH-CH2),
3.16–3.10 (q, J = 7.32Hz, 4H, 2 × CH2-CH3), 2.77–2.73 (t,
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J = 7.40Hz, 2H, S-CH2-CH2), 2.34–2.24 (m, 2H, CH-CH2-
CH2-S), 2.19 (s, 3H, CH3-S), 1.35–1.31 (t, J = 7.32Hz, 6H, 2
× CH3-CH2) ppm. 13C-NMR (Dioxane, 100MHz) δ: 173.8,
132.7, 131.2 (2 × CH aromatic), 129.5, (2 × CH aromatic),
57.7, 49.8, 43.1 (CH2), 30.8, 29.5, 16.2, 11.4 (CH3) ppm.
IR (KBr) cm−1: 3028 (CH aromatic), 2945 (CH aliphatic),
1722 (C=O), 1620 (C=C), 1200, 1126 (SO2 two bands) 698
(Ar-H). Anal. Calcd. for C16H26N2O3S2 (358.53): C, 53.60;
H, 7.31; N, 7.81. Found: C, 53.55; H, 7.22; N, 7.69.
(7)N,N-Diethyl-3-methyl-2-(phenylmethylsulfonamido)but-
anamide, 18. Yield 0.94 g (97.3%); mp 226–230◦C; Rf =
0.69. 1H-NMR (D2O, 400MHz) δ: 7.50 (s, 5H, Ar-H),
4.25 (s, 2H, CH2-SO2), 4.00-3.97 (d, J = 2.84Hz, 1H, CH-
CH-CON), 3.17–3.11 (q, J = 7.32Hz, 4H, 2 × CH2-CH3),
2.45–2.38 (m, 1H, CH), 1.36–1.32 (t, J = 7.32Hz, 6H, 2
× CH3-CH2), 1.15–1.13 (d, J = 7.00Hz, 3H, CH3-CH),
1.12–1.10 (d, J = 7.00Hz, 3H, CH3-CH) ppm. 13C-NMR
(Dioxane, 100MHz) δ: 173.8 (C=O), 132.7, 131.2 (2 × CH
aromatic), 129.5 (2 × CH aromatic), 128.9, 60.8, 57.7, 49.8,
43.1 (CH2), 16.2, 15.5, 11.4 (CH3) ppm. IR (KBr) cm−1:
3053 (CH aromatic), 2945 (CH aliphatic), 1718 (C=O),
1611 (C=C), 1219, 1194 (SO2 two bands), 696 (Ar-H). Anal.
Calcd. for C16H26N2O3S (326.46): C, 58.87; H, 8.03; N, 8.58.
Found: C, 59.01; H, 7.96; N, 8.61.
(8)N,N-Diethyl-3-hydroxy-2-(phenylmethylsulfonamido)
butanamide, 19. Yield 0.78 g (80.2%); mp 245◦C (dec); Rf
= 0.53. 1H-NMR (D2O, 400MHz) δ: 7.55 (s, 5H, Ar-H),
4.54–4.52 (m, 1H, CH-CH-CH3), 4.31 (s, 2H, CH2-SO2),
4.09–4.08 (d, J = 3.96Hz, 1H, CH-CH-CON), 3.22–3.17 (q,
J = 7.32Hz, 4H, 2 × CH2-CH3), 2.85 (s, 1H, OH), 1.49–1.47
(d, J = 6.60Hz, 3H, CH3-CH), 1.41–1.37 (t, J = 7.32Hz,
6H, 2 × CH3-CH2) ppm. 13C-NMR (Dioxane, 100MHz)
δ: 173.5 (C=O), 132.9, 131.3 (2 × CH aromatic), 129.5 (2
× CH aromatic), 128.9, 61.2, 58.1, 49.5, 42.5 (CH2), 16.6,
11.1 (CH3) ppm. IR (KBr) cm−1: 3396 (OH), 3030 (CH
aromatic), 2945 (CH aliphatic), 1720 (C=O), 1601 (C=C),
1221, 1194 (SO2 two bands), 694 (Ar-H). Anal. Calcd. for
C15H24N2O4S (328.43): C, 54.86; H, 7.37; N, 8.53. Found: C,
54.71; H, 7.26; N, 8.65.
(9)N1,N1-Diethyl-2-(phenylmethylsulfonamido)pentanedi-
amide, 20. Yield 0.98 g (93.2%); mp 251–253◦C; Rf = 0.58.
1H-NMR (D2O, 400MHz) δ: 7.51 (s, 5H, Ar-H), 4.52–4.48
(dd, J1 = 5Hz, J2 = 14.32Hz, 1H, NOC-CH-CH2a,b), 4.26
(s, 2H, CH2-SO2), 3.17–3.12 (q, J = 7.32Hz, 4H, 2 ×
CH2-CH3), 2.67–2.60 (m, 1H, CHa of CH2), 2.53–2.48 (t, J
= 8Hz, 2H, CO-CH2-CH2), 2.30–2.24 (m, 1H, CHb of CH2),
1.37–1.33 (t, J = 7.32Hz, 6H, 2×CH3-CH2) ppm. 13C-NMR
(Dioxane, 100MHz) δ: 182.7 (C=O), 177.1 (C=O), 132.6,
131.2 (2 × CH aromatic), 129.5 (2 × CH aromatic), 128.9,
57.7, 53.3, 43.1 (CH2), 30.1, 25.2, 11.4 (CH3) ppm. IR (KBr)
cm−1: 3075 (NH), 3053 (CH aromatic), 2951 (CH aliphatic),
1703 (C=O), 1659 (C=O of CON), 1601 (C=C), 1221, 1193
(SO2 two bands), 696 (Ar-H). Anal. Calcd. for C16H25N3O4S
(355.46): C, 54.06; H, 7.09; N, 11.82. Found: C, 53.95; H,
6.88; N, 12.01.
(10)N,N-Diethyl-3-phenyl-2-(phenylmethylsulfonamido)
propanamide, 21. Yield 1.00 g (90.2%); mp 227–229◦C;
Rf = 0.70. 1H-NMR (D2O, 400MHz) δ: 7.49 (s, 10H, 2
× Ar-H), 4.39–4.36 (dd, J1 = 5.60Hz, J2 = 7.60Hz, 1H,
NOC-CH-CH2a,b), 4.24 (s, 2H, CH2-SO2), 3.44–3.39 (dd,
J1 = 5.60Hz, J2 = 20.00Hz, 1H, CHa of CH2a,b), 3.31–3.26
(dd, J1 = 7.60Hz, J2 = 20.00Hz, 1H, CHb of CH2a,b),
3.16–3.10 (q, J = 7.32Hz, 4H, 2 × CH2-CH3), 2.78 (s, 2H,
CH2), 1.35–1.31 (t, J = 7.32Hz, 6H, 2 × CH3-CH2) ppm.
13C-NMR (Dioxane, 100MHz) δ: 172.4 (C=O), 135.1, 132.7,
131.2 (2 × CH aromatic), 130.3 (2 × CH aromatic), 130.1
(2 × CH aromatic), 129.5 (2 × CH aromatic), 128.9 (2 ×
CH aromatic), 57.8, 55.2, 43.1 (CH2), 36.5, 11.5 (CH3) ppm.
IR (KBr) cm−1: 2976 (NH), 2828 (CH aromatic), 2774 (CH
aliphatic), 1736 (C=O), 1620 (C=C), 1206, 1153, 1148 (SO2
two bands), 698 (Ar-H). Anal. Calcd. for C20H26N2O3S
(374.51): C, 64.14; H, 7.00; N, 7.48. Found: C, 64.00; H, 6.84;
N, 7.29.
(11) 4-(3-(Diethylamino)-3-oxo-2-(phenylmethylsulfonamido) pr
opyl)phenylphenylmethanesulfonate, 22. Yield 1.44 g (89.3%);
mp 265◦C (dec); Rf = 0.69. 1H-NMR (D2O, 400MHz) δ:
7.50 (s, 10H, 2 × Ar-H), 7.29–7.27 (d, J = 8.00Hz, 2H, Ar-
H), 6.99–6.97 (d, J = 8.00Hz, 2H, Ar-H), 4.37–4.33 (dd, J1
= 5.60Hz, J2 = 7.60Hz, 1H, NOC-CH-CH2a,b), 4.26 (s, 2H,
CH2-SO2), 3.37–3.32 (dd, J1 = 5.60Hz, J2 = 20.00Hz, 1H,
CHa of CH2a,b), 3.26–3.21 (dd, J1 = 7.60Hz, J2 = 20.00Hz,
1H, CHb of CH2a,b), 3.17–3.12 (q, J = 7.32Hz, 4H, 2 × CH2-
CH3), 1.37–1.33 (t, J = 7.32Hz, 6H, 2 × CH3-CH2) ppm.
13C-NMR (Dioxane, 100MHz) δ: 172.4 (C=O), 155.9, 141.3,
131.8 (2 × CH aromatic), 131.3 (2 × CH aromatic), 129.6
(2 × CH aromatic), 129.0 (2 × CH aromatic), 126.6, 123.0
(2 × CH aromatic), 116.9 (2 × CH aromatic), 111.6 (2 ×
CH aromatic), 57.8, 55.2, 43.2 (CH2), 35.6, 11.6 (CH3) ppm.
IR (KBr) cm−1: 3058 (NH), 3036 (CH aromatic), 2951 (CH
aliphatic), 1719 (C=O), 1601 (C=C), 1219, 1196, 1148 (SO2
two bands), 696 (Ar-H). Anal. Calcd. for C27H32N2O6S2
(544.69): C, 59.54; H, 5.92; N, 5.14. Found: C, 59.43; H, 5.99;
N, 4.98.
4.3. Antibacterial Activity Assays. The antimicrobial prop-
erties of the sulfonamides were investigated in the form of
the general sensitivity testing and minimum inhibitory con-
centration (MIC) with respect to freshly cultured targeted
organisms. The two organisms of interest in this present
study are one gram positive (Staphylococcus aureus ATCC
6538) and one gram negative (Escherichia coli ATCC 25922)
organisms which are associated with the gastrointestinal tract
damage in man and animal.
4.3.1. Preparation of the Inoculum. The standard strains of
S. aureus and E. coli used were obtained from Test Center of
Antimicrobial Materials, TIPC, Beijing. No clinically isolated
organism was used based on inavailability of such as at the
time of this study. The strains were propagated on nutrient
agar plates and maintained on the plate at 4◦C. The isolates
were subcultured in nutrient broth at 37◦C for 8 h prior to
antibacterial testing.
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4.3.2. Antibacterial Sensitivity Testing of the Synthesized Com-
pounds. Agar well diffusion technique as described by
Adeniyi and coworkers was used to determine the antibac-
terial activity of the synthesized compounds [66]. Sensitivity
test agar plates were seeded with 0.1mL of an overnight
culture of each bacterial strain (equivalent to 107–108
CFUmL−1). The seeded plates were allowed to set and a
standard cork borer of 8mm diameter was used to cut
uniform wells on the surface of the agar. The wells were
then filled with 0.3mL of each sulfonamide solution in
an appropriate solvent at a concentration of 1000 μg/mL
(0.02 g of sulfonamide dissolved in 20mL distilled water).
All the plates were incubated at 37◦C for 24 h. The assay was
conducted at regular intervals of 24 h until a marked decline
in the potency of the sulfonamide solution to inhibit the
growth of the test organisms was noticed. Zones of clearance
round each well means inhibition and the diameter of such
zones were measured. The procedure was repeated for the
streptomycin (standard).
4.3.3. Determination of Minimum Inhibitory Concentration
(MIC). Agar well dilution method as described by Russell
and Furr was used to determine the minimum inhibitory
concentration (MIC) of the sulfonamides and streptomycin
[69]. Different dilutions of the sulfonamides were prepared
first at ≤100 μg/mL to give final concentrations in the range
of 100, 50, 25, 12.5, 6.25, and 1.8 μg/mL. The different
dilutions of sulfonamide derivatives that could not inhibit
the microbial growth at ≤100 μg/mL were later prepared
at ≤1000 μg/mL to give final concentrations in the range
of 1000, 500, 250, 125, and 62.5 μg/mL. Two milliliter
(2mL) of each dilution was mixed with 18mL of Mueller
Hinton agar (MHA, Difco, France) and poured into Petri
dishes and allowed to set. The agar was streaked with an
overnight broth culture of the bacterial strains and incubated
overnight. The plates were then examined for the presence
or absence of growth. The minimum concentration that
completely inhibited macroscopic growth was regarded as
the minimum inhibitory concentration of the respective
sulfonamide. The procedure was repeated for streptomycin
(standard). Selectivity index (SI) is the ratio of the zone of
the inhibition of compound to that of the streptomycin.
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